Please check your internet connection and try again.
# Walethmade%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide
## Overview
Walethmade%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide is a non-specific cholinesterase inhibitor.
## Primary Indications
* Treatment of myasthenia gravis.
* Reversal of neuromuscular blockade caused by non-depolarizing neuromuscular blocking agents.
## Adult Dosing
* **Myasthenia Gravis:** The usual starting dose is 15 mg orally every 3-4 hours as needed. Doses can be increased based on patient response, typically not exceeding 1500 mg/day. Titration should be gradual.
* **Reversal of Neuromuscular Blockade:** 0.5 mg to 1 mg intravenously, often administered concurrently with atropine or glycopyrrolate to counteract muscarinic effects. The total dose should not exceed 5 mg intravenously in a single administration.
## Pediatric Dosing
Dosing in pediatric patients is not well-established and should be guided by specialist consultation and institutional protocols.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Doses may need to be reduced.
* **Hepatic Impairment:** Use with caution. Doses may need to be reduced.
* **Respiratory Impairment:** Dose adjustments are critical due to the risk of bronchospasm and respiratory muscle weakness.
## Contraindications
* Known hypersensitivity to Walethmade%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide or its components.
* Gastrointestinal or urinary tract obstruction.
* Peritoneal dialysis.
## Adverse Effects
Common adverse effects include: nausea, vomiting, diarrhea, abdominal cramps, increased salivation, sweating, bradycardia, and muscle cramps. More serious effects can include bronchospasm and cholinergic crisis.
## Key Drug Interactions
* **Succinylcholine:** Prolongs neuromuscular blockade.
* **Non-depolarizing neuromuscular blockers:** Antagonizes their effects.
* **Aminoglycoside antibiotics:** May potentiate neuromuscular blockade.
* **Beta-blockers:** May potentiate bradycardia.
* **Muscarinic antagonists (e.g., atropine):** Used to counteract peripheral muscarinic effects.
## Monitoring
* **Myasthenia Gravis:** Monitor for improvements in muscle strength, ptosis, and bulbar function. Assess for signs of cholinergic or myasthenic crisis.
* **Reversal of Neuromuscular Blockade:** Monitor for return of neuromuscular function (e.g., train-of-four monitoring).
## Clinical Pearls
* Administer parenterally with an anticholinergic agent like atropine to mitigate muscarinic side effects.
* Overdosing can lead to a cholinergic crisis, characterized by excessive muscle weakness, salivation, and respiratory distress, which can be difficult to distinguish from a myasthenic crisis.
* Oral administration may be delayed in onset and duration compared to parenteral.
***
**Disclaimer:** This information is intended for clinical use by healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant literature before making treatment decisions.
